Comparative Pharmacology
Head-to-head clinical analysis: MELLARIL versus MILPROSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MELLARIL versus MILPROSA.
MELLARIL vs MILPROSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioridazine is a phenothiazine antipsychotic that blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors, and also blocks alpha-adrenergic receptors, histamine H1 receptors, and muscarinic M1 receptors.
Milprosa is a progesterone receptor agonist that induces and maintains endometrial receptivity, inhibits uterine contractions, and suppresses gonadotropin release.
Typical adult dose: 10-25 mg orally 3 times daily. Maximum dose: 200 mg/day.
MILPROSA is not a recognized drug; assuming a typo for milrinone? If milrinone: IV loading dose 50 mcg/kg over 10 minutes, then continuous IV infusion 0.375-0.75 mcg/kg/min.
None Documented
None Documented
Terminal elimination half-life 21-24 hours; steady-state achieved within 5-7 days
14 hours (range 10–18); prolonged in renal impairment (up to 40 hours)
Primarily renal (70-80% as metabolites, <1% unchanged); biliary/fecal (20-30%)
Renal (70% unchanged, 20% as inactive metabolites); fecal (10%)
Category C
Category C
Antipsychotic
Antipsychotic